# Neurocrine Biosciences Inc (NBIX) insider trading

> In the 12 months to Nov 6, 2026, 15 NBIX insiders reported open-market sales of $80.2M across 26 filings; no open-market purchases were filed.

Canonical: https://massive.com/quote/nbix/insider-trading
Latest filing: 2026-11-05 (last 12 months; source: SEC EDGAR)
Source: Massive (https://massive.com/docs/llms.txt)

## Summary

| Measure | Value | Detail |
| --- | --- | --- |
| Open-market sales | $80.2M | 26 filings · 15 insiders |
| Open-market purchases | $0 | 0 filings |
| Pre-arranged sales (10b5-1) | 26 of 26 | All $80.2M sold was pre-arranged |

## Open-market trades by insider

| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
| --- | --- | --- | --- | --- | --- | --- |
| Kevin Charles Gorman | Director | $37.8M | — | 1 | 100% of sales | 2026-05-21 |
| Julie Cooke | Chief Human Resources Officer | $5.8M | — | 1 | 100% of sales | 2026-06-04 |
| Kyle Gano | Chief Executive Officer | $4.8M | — | 1 | 100% of sales | 2026-01-20 |
| George J. Morrow | Director | $4.5M | — | 2 | 100% of sales | 2026-11-03 |
| Darin Lippoldt | Chief Legal Officer | $4.2M | — | 3 | 100% of sales | 2026-07-13 |
| Stephen A. Sherwin | Director | $4.1M | — | 1 | 100% of sales | 2026-06-09 |
| Ingrid Delaet | Chief Regulatory Officer | $3.7M | — | 3 | 100% of sales | 2026-07-13 |
| Jude Onyia | Chief Scientific Officer | $3.5M | — | 2 | 100% of sales | 2026-06-02 |
| William H. Rastetter | Director | $2.7M | — | 1 | 100% of sales | 2025-11-06 |
| Richard F. Pops | Director | $2.4M | — | 1 | 100% of sales | 2026-05-18 |
| Gary A. Lyons | Director | $2.3M | — | 1 | 100% of sales | 2025-12-04 |
| Leslie V. Norwalk | Director | $2.0M | — | 4 | 100% of sales | 2026-07-30 |
| Eric Benevich | Chief Commercial Officer | $1.2M | — | 2 | 100% of sales | 2026-09-10 |
| David W. Boyer | Chief Corp. Affairs Officer | $739.1K | — | 2 | 100% of sales | 2026-09-15 |
| Matt Abernethy | Chief Financial Officer | $363.3K | — | 1 | 100% of sales | 2026-09-15 |

## Open-market trades by filing

26 filings in the last 12 months, newest first.

| Filed | Traded | Insider | Role | Type | Shares | Avg price | Value | Held after | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2026-11-03 | 2026-10-30 | George J. Morrow | Director | Sale (10b5-1) | 15,000 | $155.73 | $2.3M | 15,560 | — |
| 2026-09-15 | 2026-09-14 | Matt Abernethy | Chief Financial Officer | Sale (10b5-1) | 2,311 | $157.20 | $363.3K | 42,808 | — |
| 2026-09-15 | 2026-09-14 | David W. Boyer | Chief Corp. Affairs Officer | Sale (10b5-1) | 826 | $157.45 | $130.1K | 8,722 | — |
| 2026-09-10 | 2026-09-09 | Eric Benevich | Chief Commercial Officer | Sale (10b5-1) | 2,154 | $154.61 | $333.0K | 64,408 | — |
| 2026-07-30 | 2026-07-28 | Leslie V. Norwalk | Director | Sale (10b5-1) | 1,250 | $182.01 | $227.5K | 1,588 | — |
| 2026-07-13 | 2026-07-09 | Darin Lippoldt | Chief Legal Officer | Sale (10b5-1) | 10,000 | $179.60 | $1.8M | 54,729 | — |
| 2026-07-13 | 2026-07-10 | Ingrid Delaet | Chief Regulatory Officer | Sale (10b5-1) | 4,367 | $181.02 | $790.5K | 16,225 | — |
| 2026-07-09 | 2026-07-07 | Ingrid Delaet | Chief Regulatory Officer | Sale (10b5-1) | 14,571 | $178.65 | $2.6M | 16,225 | — |
| 2026-06-30 | 2026-06-26 | Darin Lippoldt | Chief Legal Officer | Sale (10b5-1) | 10,000 | $170.15 | $1.7M | 54,729 | — |
| 2026-06-09 | 2026-06-05 | Stephen A. Sherwin | Director | Sale (10b5-1) | 25,000 | $165.32 | $4.1M | 23,532 | — |
| 2026-06-08 | 2026-06-04 | Leslie V. Norwalk | Director | Sale (10b5-1) | 1,250 | $168.06 | $210.1K | 2,838 | — |
| 2026-06-04 | 2026-06-02 | Julie Cooke | Chief Human Resources Officer | Sale (10b5-1) | 36,937 | $156.22 | $5.8M | 39,631 | — |
| 2026-06-02 | 2026-06-01 | Jude Onyia | Chief Scientific Officer | Sale (10b5-1) | 11,000 | $160.25 | $1.8M | 25,846 | — |
| 2026-06-02 | 2026-05-29 | Ingrid Delaet | Chief Regulatory Officer | Sale (10b5-1) | 2,261 | $156.71 | $354.3K | 16,225 | — |
| 2026-05-29 | 2026-05-27 | Jude Onyia | Chief Scientific Officer | Sale (10b5-1) | 11,000 | $155.53 | $1.7M | 25,846 | — |
| 2026-05-28 | 2026-05-26 | David W. Boyer | Chief Corp. Affairs Officer | Sale (10b5-1) | 3,888 | $156.64 | $609.0K | 7,799 | — |
| 2026-05-21 | 2026-05-19 | Kevin Charles Gorman | Director | Sale (10b5-1) | 245,088 | $154.33 | $37.8M | 511,293 | — |
| 2026-05-18 | 2026-05-15 | Richard F. Pops | Director | Sale (10b5-1) | 15,000 | $157.65 | $2.4M | 34,480 | — |
| 2026-05-14 | 2026-05-12 | Leslie V. Norwalk | Director | Sale (10b5-1) | 3,810 | $155.01 | $590.6K | 2,429 | — |
| 2026-01-20 | 2026-01-16 | Kyle Gano | Chief Executive Officer | Sale (10b5-1) | 36,400 | $132.70 | $4.8M | 140,407 | — |
| 2025-12-17 | 2025-12-15 | Leslie V. Norwalk | Director | Sale (10b5-1) | 6,190 | $152.78 | $945.7K | 6,239 | — |
| 2025-12-10 | 2025-12-08 | Darin Lippoldt | Chief Legal Officer | Sale (10b5-1) | 4,376 | $159.65 | $698.6K | 43,405 | — |
| 2025-12-04 | 2025-12-03 | Gary A. Lyons | Director | Sale (10b5-1) | 15,000 | $152.61 | $2.3M | 120,482 | — |
| 2025-12-02 | 2025-11-28 | Eric Benevich | Chief Commercial Officer | Sale (10b5-1) | 5,970 | $151.74 | $905.9K | 44,893 | — |
| 2025-11-26 | 2025-11-25 | George J. Morrow | Director | Sale (10b5-1) | 15,000 | $143.37 | $2.2M | 7,068 | — |
| 2025-11-06 | 2025-11-05 | William H. Rastetter | Director | Sale (10b5-1) | 18,000 | $151.82 | $2.7M | 40,360 | — |

## Other insider activity (not market trades)

- Option exercises: 78 records
- Tax withholding: 58 records
- Grants and awards: 20 records
- Gifts: 6 records

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

## How to read this page

- **Open-market purchase or sale**: A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- **Pre-arranged (10b5-1)**: The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- **Filing date**: Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.

## FAQ

### Has Neurocrine Biosciences Inc's CEO sold stock?

Yes. Kyle Gano (CEO) sold 36,400 shares ($4.8M) in Jan 2026, all under a pre-arranged 10b5-1 plan.

### How current is NBIX’s insider data?

These are NBIX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

### What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

## Live data

This page joins two Massive endpoints: Form 4 filings and daily prices. The NBIX Form 4 request:

- `GET https://api.massive.com/stocks/filings/vX/form-4?tickers=NBIX&filing_date.gte=2025-11-06&sort=filing_date.desc&limit=500`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Neurocrine Biosciences Inc (NBIX) stock price](https://massive.com/quote/nbix.md)
- [Recent insider trading](https://massive.com/quote/insider-trading.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms